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INTRODUCTION
Both the American Heart Association (AHA) 
in 20081 and the UK National Institute for 
Health and Care Excellence (NICE) in 20112 
suggest the need for further research 
into treatment-resistant hypertension 
(TRH). Apparent-TRH (aTRH) is defined 
as uncontrolled blood pressure (BP) 
in patients taking ≥3 differing groups of 
antihypertensive medications (one of which 
must be a diuretic-type medication) or 
patients who are taking ≥4 medications 
regardless of type and BP level.3 The term 
apparent is used because some of this 
group will have true treatment-resistant 
hypertension (tTRH), others undiagnosed 
secondary hypertension, and more have 
pseudo-resistant hypertension.4 Pseudo-
resistance exists when factors such as 
non-adherence to medications, white-
coat hypertension (WCH), inadequate drug 
dosing, and lifestyle issues are responsible 
for the seemingly poor BP control.3,4–6
The Lancet commission on hypertension 
stated that:
‘Ideally, diagnosis, initiation, and titration of 
treatment should be guided by ambulatory, 
home, or automated unobserved blood 
pressure ...’.7 
It went on to note:
‘Objective assessment of adherence 
to therapy is possible by testing for the 
presence of drug metabolites in body fluids, 
particularly urine. Measurement methods 
… are sensitive, reproducible, relatively 
inexpensive, and could help treatment 
decisions, particularly in patients with 
difficult-to-control hypertension.’  7
A number of hospital-based studies have 
used mass spectrometry urine analysis in 
patients with aTRH demonstrating non-
adherence rates of 25% to 53%.8,9 To the 
present authors’ knowledge, no similar 
study has yet been performed in primary 
care.
This study aimed to examine, for the 
first time in primary care, the feasibility of 
establishing non-adherence to medication 
using mass spectrometry urine analysis. 
Operationalisation would be established 
by at least 50% of patients agreeing to 
participate and at least 95% of samples 
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Abstract
Background
Apparent treatment-resistant hypertension 
(aTRH) is defined as uncontrolled blood 
pressure (BP) in patients taking three or more 
antihypertensive medications. Some patients will 
have true treatment-resistant hypertension, some 
undiagnosed secondary hypertension, while others 
have pseudo-resistance. Pseudo-resistance occurs 
when non-adherence to medication, white-coat 
hypertension (WCH), lifestyle, and inadequate drug 
dosing are responsible for the poorly controlled BP.
Aim
To examine the feasibility of establishing non-
adherence to medication, for the first time in 
primary care, using mass spectrometry urine 
analysis. Operationalisation would be established 
by at least 50% of patients participating and 95% 
of samples being suitable for analysis. Clinical 
importance would be confirmed by >10% of 
patients being non-adherent. 
Design and setting
Eligible patients with aTRH (n = 453) in 15 university 
research-affiliated Irish general practices were 
invited to participate.
Method
Participants underwent mass spectrometry urine 
analysis to test adherence and ambulatory BP 
monitoring (ABPM) to examine WCH. 
Results
Of the eligible patients invited, 52% (n = 235) 
participated. All 235 urine samples (100%) were 
suitable for analysis: 174 (74%) patients were fully 
adherent, 56 (24%) partially adherent, and five 
(2%) fully non-adherent to therapy. A total of 206 
patients also had ABPM, and in total 92 (45%) were 
categorised as pseudo-resistant. No significant 
associations were found between adherence status 
and patient characteristics or drug class.
Conclusion
In patients with aTRH, the authors have 
established that it is feasible to examine 
non-adherence to medications using mass 
spectrometry urine analysis. One in four patients 
were found to be partially or fully non-adherent.  
Further research on how to incorporate this 
approach into individual patient consultations 
and its associated cost-effectiveness is now 
appropriate.
Keywords
hypertension; primary care; pseudo-resistance; 
treatment adherence; urinalysis.
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being suitable for analysis. A participation 
rate of 50% was chosen as patients were 
being asked to participate in a research 
study rather than a routine clinical service 
within the practice. Similar studies 
conducted by the Health Research Board 
Primary Care Clinical Trial Network Ireland 
have participation rates of circa 30% (N 
Burke, unpublished data, 2019). Clinical 
utility would be confirmed by >10% of 
patients being non-adherent as this was 
considered to be sufficiently common to 
impact on clinical care. 
METHOD
Participants
The authors have previously published a 
cross-sectional study on the prevalence of 
aTRH in primary care and identified a cohort 
of patients with this condition (Figure 1).10,11 
Patients who were either on four blood 
pressure-lowering medications or on at 
least three with raised blood pressure were 
eligible.
For this study, 569 patients from 15 
university research-affiliated Irish practices 
were eligible for inclusion. GPs were asked 
to review the names of these patients to 
confirm their continuing eligibility and that 
they were not suffering from significant 
morbidity, which would preclude their 
ability to participate, such as those with 
acute oncological issues, severe psychiatric 
illness, or individuals who were housebound. 
All others were invited to attend their 
general practice on a specific day, between 
June 2016 and March 2017, to undergo urine 
assessment and ambulatory BP monitoring 
(ABPM). Patients were informed by letter 
that the urine assessment was to examine 
‘the success of your tablets in controlling 
your blood pressure’. All participants were 
required to give explicit signed consent. 
A comparison was also planned to 
examine differences between participants 
and non-participants (see Table 1.) 
Urine sample processing 
Urine samples were conveyed to the main 
laboratory at University Hospital Galway via 
the routine primary care laboratory transport 
service. They were then redirected on the 
same day to the Clinical Research Facility, 
Galway, and stored at –80°C. Drug assays 
were then performed in batches at the 
Biological Mass Spectrometry Core Facility 
at the National University of Ireland, Galway, 
utilising a methodology similar to Jung’s and 
Tomaszewski’s.8,9 Technical aspects of the 
mass spectrometry performed, including 
sample preparation and sampling, are 
available from the authors on request. The 
authors built assays to test 20 of the most 
commonly prescribed antihypertensive 
drugs; technical difficulties prevented 
successful assessment of five common 
drugs (Box 1).
Drug metabolites were also screened 
for where indicated. Some angiotensin-
converting enzyme (ACE) inhibitors have an 
unusual pharmacokinetic property, in that 
they exist primarily as a pro-drug and are 
broken down by the liver to various active 
metabolites; this stands true for enalapril, 
perindopril, and ramipril.12 The half-life of 
the various drug metabolites vary and some 
are quite short, for example, perindopril 
has a half-life of 3–10 hours.13 The 
pharmacokinetics of the breakdown of ACE 
inhibitors are not linear and many complex 
binding issues are involved. Metabolites are 
largely excreted by the kidney but variation 
exists as some are also partially excreted by 
the liver itself.14
Patients were described as being fully 
or partially adherent, or fully non-adherent 
depending on the ratio of the number of 
drugs present in their urine divided by the 
number of drugs prescribed. Prescribed 
drugs that could not be identified were not 
included in the calculation of adherence 
ratios. 
Ambulatory blood pressure monitoring
White-coat hypertension is defined 
as having an elevated clinic BP reading 
≥140/90 mmHg but a normal 24-hour ABPM 
daytime mean value (≤135/85 mmHg). The 
Meditech ABPM-05 (PMS [Instruments] 
Ltd) device was used.15 The NICE guideline 
for the use of ABPM was applied to ensure 
validity.2 Clinic-based BP was the last 
How this fits in
Both the American Heart Association (AHA) 
in 2008 and the UK National Institute for 
Health and Care Excellence (NICE) in 2011 
suggest the need for further research into 
treatment-resistant hypertension (TRH). 
Non-adherence to therapy and white-
coat hypertension (WCH) are significant 
causes of pseudo-resistance (false 
resistance). Ambulatory blood pressure 
monitoring is successful in ruling out 
WCH, but non-adherence to therapy is 
more difficult to detect, especially when 
it is non-intentional. The authors have 
shown that testing a patient’s urine, with 
consent, for evidence of ingestion of their 
antihypertensive medications is feasible 
in primary care. Further work measuring 
the effect this has on the doctor–patient 
relationship and potential impact on patient 
prognosis is needed.
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recorded BP on the patient’s file, within the 
last year.
Statistical analysis
Graphical, univariate and multivariate, 
summaries were created for all patient 
characteristics in order to identify any 
anomalies or outliers. Summary statistics 
were generated that were appropriate for 
the explanatory variable in question.
Two sample t-tests, unequal variance, 
were used to compare the mean of 
covariates between the groups (adherent 
and partially or fully non-adherent), and a 
two-sample comparison of proportions (or 
χ2 test) to compare factors.
Multivariable logistic regression was used 
to model the association between the (log) 
odds of adherence and explanatory variables 
of interest, such as patient characteristics, 
number of and type of medications, 
morbidity, or BP. These variables were 
identified through a review of the existing 
literature. In addition, variable selection was 
also performed using elastic nets and tree-
based methods, but this yielded no further 
advances in knowledge.16 All analyses were 
performed using R (version 3.5).
RESULTS
A total of 453 eligible patients with aTRH 
were invited and 235 (52%) participated 
(that is, agreed to having urinalysis). All 
235 (100%) samples were successfully 
transported to the laboratory and analysed. 
Figure 1 illustrates participant flow 
through the study and Table 1 shows the 
characteristics of both participants and 
non-participants (those who did not have 
the urinalysis] There were no apparent 
Figure 1. Participant flow through study. 
ABPM = ambulatory BP monitoring. aTRH = apparent 
treatment-resistant hypertension. WCH = white-coat 
hypertension. 
Excluded (n = 49 526)
• Do not have aTRH 2
(Excluded n = 77)
• One practice was excluded as it was
 outside the catchment area for a
 tertiary hospital’s hypertension clinic
• Patients were not invited to participate
 at the advice of their GP due to
 significant morbidity and/or infirmity
 (n = 95)
• Patients had either moved practices,
 died, or were no longer taking
 medications for blood pressure,
 between the cross-sectional study
 and urine donation (n = 21)
Excluded (n = 116)
Base adult population in 16 practices
(n = 50 172)
Total number of patients with aTRH
(n = 646)

































Number of patients with aTRH invited for
assessment (n = 453)
Study participants: 
n = 235/453 (52%)
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differences between the two groups; the 
non-participant group had slightly more 
females and slightly higher proportions of 
diabetes, kidney disease, or cardiac failure. 
Table 2 provides details on the 
antihypertensive medications they were 
receiving. A total of 860 antihypertensive 
drugs were prescribed, an average of 
3.7 medications each individual, for these 
235 participants. Mass spectrometry urine 
analysis was performed for 710 of these 
drugs, 82.6% of the total number of drugs 
prescribed. The authors demonstrated 
that 174 patients were fully adherent to 
treatment (74%), 56 partially adherent 
(24%), and five fully non-adherent (2%). 
Twelve patients declined ABPM and 
17 ABPM reports were suboptimal for 
assessment, as per NICE criteria.2 A total of 
206 (45%) completed valid ABPM and 28% 
had WCH (n = 58). Notably, 45% (92/206) 
of patients had pseudo-resistance. This is 
best calculated by using those who did both 
urine testing and ABPM as the denominator 
(n = 206), and being mindful that 27 patients 
had both WCH and non-adherence to 
therapy, and can only be included a single 
time, thus reducing the impact of the 
numerator. However, this figure must be 
interpreted cautiously as lifestyle factors 
and comedications were not evaluated. 
There were no significant associations 
between the adherence status of 
participants and patient characteristics, 
number or type of medications used, 
morbidity, or BP (Table 3). 
Table 1. Characteristics of patients with apparent treatment-resistant 
hypertension who gave a urine sample for urine toxicology analysis 
(n = 235) versus those who did not (non-participants) (n = 218)
 Participants Non-participants 
Characteristics (n = 235) (n = 218)
Mean age, years (SD) 70.8 (10.6) 70.0 (12.8) 
Female sex, n (%) 98 (41.7) 105 (48.2) 
PCRS eligibility,a n (%) 196 (83.4) 172 (78.9)
Diabetes, n (%) 71 (30.2) 79 (36.2) 
Chronic kidney disease, n (%) 80 (34.0) 91 (41.7) 
Cardiac failure, n (%) 23 (9.8) 30 (13.8)
Mean systolic clinic BP, mmHg (SD) 142 (18.1) 142.9 (16.4) 
Mean diastolic clinic BP, mmHg (SD) 78.2 (10.9) 77.5 (11.4) 
aPrimary care reimbursement service eligible, which confirms access to free GP visits and/or medications (based on 
individual means testing). BP = blood pressure. PCRS = primary care reimbursement service. SD = standard deviation. 
Box 1. Antihypertensive drugs tested during mass spectrometry 
urine analysis 
Drug number Detectable medications Drug number Undetectable medications
1 Amiloride 21 Felodipine
2 Amlodipine 22 Lercanidipine
3 Atenolol 23 Nebivolol
4 Bendroflumethiazide 24 Spironolactone
5 Bisoprolol 25 Candesartan
6 Bumetanide  
7 Diltiazem  
8 Doxazosin  
9 Enalapril (enalaprilat)a  
10 Furosemide  
11 HCTZ  
12 Indapamide  
13 Losartan  
14 Lisinopril  
15 Olmesartan  
16 Perindopril (perindoprilat)a  
17 Ramipril (ramiprilat)a  
18 Telmisartan  
19 Valsartan  
20 Verapamil  
aACE-inhibitor metabolites. HCTZ = hydrochlorothiazide. 
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Table 2. Pharmacological 
characteristics of 
antihypertensive therapy 
in patients with apparent 
treatment-resistant 
hypertension who gave 
a urine sample for mass 
spectrometry urine analysis 
(N = 235)
Pharmacological characteristics a n (%)
Mean number of BP  3.7 (0.7) 
medications per  
patient (SD)
Combination medications 153 (65.1)
Three medications only 103 (43.8)
ACE inhibitors 100 (42.6)
Angiotensin blockers 125 (53.2)
Beta-blockers 146 (62.1)
Calcium channel blockers 176 (74.9)
Diuretics 225 (95.7)
Alpha-blockers 40 (17.0)
Other vasodilators,  1 (<1) 
direct renin inhibitors, % 
aNumber of participants and percentage, unless 
specified. ACE = angiotensin-converting enzyme. 
BP = blood pressure. SD = standard deviation.
Table 3. Comparison of summary statistics of different covariates 
(patient characteristics, drug class, number of medications, use 
of combined medications, morbidity, and ABPM readings) among 
adherent and non-adherent (partially or fully non-adherent) groups 
(N = 235)
 Non-adherent Adherent  
Covariate n (%)a (n = 61) n (%)a (n = 174) P-value
Age, mean (SD) 69.9 (11.4) 69.8 (10.4) 0.956
Sex   0.923
 Male 35 (57.4) 103 (59.2)
 Female 26 (42.6) 71 (40.8)
Diabetes   0.982
 No 42 (68.9) 122 (70.1)
 Yes 19 (31.1) 52 (29.9)
Chronic kidney disease   0.429
 Not CKD 43 (70.5) 111 (63.8)
 CKD 18 (29.5) 63 (36.2)
 Angiotensin receptor blocker   0.214
 No 34 (55.7) 79 (45.4)
 Yes 27 (44.3) 95 (54.6)
Beta-blocker   0.297
 No 27 (44.3) 62 (35.6)
 Yes 34 (55.7) 112 (64.4)
ACE inhibitor   0.095 
 No 29 (47.5) 106 (60.9)
 Yes 32 (52.5) 68 (39.1)
Calcium channel blocker   0.306 
 No 21 (34.4) 46 (26.4) 
 Yes 40 (65.6) 128 (73.6)
Diuretic   0.460
 No 1 (1.6) 9 (5.2)
 Yes 60 (98.4) 165 (94.8)
3 medications   1.000
 >3 medications 34 (55.7) 98 (56.3)
 3 medications only 27 (44.3) 76 (43.7)
Combination medications   0.385
 No 18 (29.5) 64 (36.8)
 Yes 43 (70.5) 110 (63.2)
Documented CCF   0.791
 Not documented 54 (88.5) 158 (90.8)
 Documented 7 (11.5) 16 (9.2)
Mean systolic day ABPM, mmHg (SD) 137 (15.6) 135 (16.0) 0.435 
Mean diastolic day ABPM, mmHg (SD) 73.4 (11.2) 73.1 (9.82) 0.829
Mean systolic night ABPM, mmHg (SD) 131 (19.7) 129 (20.6) 0.513
Mean diastolic night ABPM, mmHg (SD) 67.8 (13.7) 66.7 (11.9) 0.609
ABPM total systolic, mmHg 135 (16.5) 133 (16.8) 0.441
ABPM total diastolic, mmHg 71.2 (11.5) 70.5 (9.80) 0.708
WCH   0.136
 No 51 (83.6) 127 (73.0)
 Yes 10 (16.4) 47 (27.0)
aNumber of participants and percentage, unless specified. ABPM = ambulatory blood pressure monitoring. 
CCF = congestive cardiac failure. WCH = white-coat hypertension.
As seen in Table 4, none of the variables 
were deemed significant predictors of 
adherence based on the logistic models 
(regular and penalised) and tree-based 
models fitted (data are available from the 
authors on request). The authors believe 
there may be some interpretive difficulties 
when using mass spectrometry urinalysis 
to identify non-adherence in patients taking 
some types of ACE inhibitors. Therefore, 
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the authors have not presented this as a 
factor determining adherence status here, 




In patients with aTRH, the authors have 
established for the first time in primary 
care that it is feasible to examine non-
adherence to medications using mass 
spectrometry urine analysis. One in four 
patients were found to be either partially 
or fully non-adherent Combining this with 
ABPM suggested that 45% of patients were 
pseudo-resistant.
The participation of 52% of patients was 
just above the suggested threshold of 50%. 
However, this was a participation rate for a 
formal research study conducted on limited 
and discrete days by staff external to the 
practice. The authors think it reasonable 
to suggest that, now that feasibility has 
been demonstrated, patient participation 
with a fully integrated service conducted by 
usual practice staff will be higher. The tasks 
of processing a patient’s urine specimen 
in order to send to the laboratory and 
performing ABPM occur daily in routine 
general practice.
In the present study, 100% of samples 
were suitable for analysis. Transporting 
urine samples safely from primary care to 
hospital laboratories and then to adjoining 
research facilities for freezing is not without 
challenges. The authors of this study have 
now shown that this process is feasible, and 
that from multiple, geographically disparate 
sites in primary care (some in excess of 
60 miles distant) urine samples can be 
safely and efficiently delivered for testing 
using routine transport systems.
The clinical importance of conducting 
the analyses was confirmed in finding that 
almost one in four patients were non-
adherent.
Strengths and limitations
This study was based in one geographical 
area with a patient participation rate of 52%. 
However, the practices are representative 
of an Irish general practice area and 
participation rates are typical for such 
research studies.17
In the logistic regression model presented 
in Table 4, it is suggested that ACE inhibitors 
may be associated with non-adherence 
(P = 0.04). As outlined previously, the 
metabolism of ACE inhibitors is complex 
and caution is required in interpretation 
of this finding. Further pharmacokinetic 
research clarifying the predictive value 
of a negative test in these instances is 
warranted. Similarly, indapamide is also 
a unique drug as it has a lengthy half-life 
and can persist in urine for up to 60 hours 
after consumption.18 Therefore a patient on 
indapamide could be incorrectly identified 
as adherent when the opposite could be 
true. 
Most drugs, ACE inhibitors and 
thiazides apart, are cytochrome P450 
dependent for metabolism. The ability to 
detect medications depends on a range 
of uncontrollable patient-specific and 
pharmacokinetic factors, which must be 
considered, such as time of last dose, 
the presence of various comorbidities 
(diabetes and chronic kidney disease), rapid 
metaboliser status (cytochrome P450), and 
whether concurrent medications are being 
taken. 
In the future, specific attention may need 
to be placed on advising participants and 
researchers about standard approaches to 
taking last doses of medications, and the 
harvest and storage of urine samples, as this 
will facilitate between-study comparisons. 
As this study confirmed that drugs were 
taken qualitatively but not quantitatively, the 
authors cannot say that drugs were taken at 
the right time or in the correct doses. 
A further limitation of the study is the 
fact that the authors performed mass 
spectrometry urine analysis for only 20 
drugs compared with 40 by Tomaszewski 
et al.9 However, these 20 accounted for 
82.6% of the cohorts prescribed drugs. The 
authors also accept that using single clinical 
BP readings as a marker for hypertension 
may be suboptimal, as day-to-day variability 
in readings is possible.
Table 4. Results from a logistic regression model to investigate 
the effect of patient characteristics of relevance on the odds of 
adherencea
 Odds ratio  95% CI P-value
Intercept 1.65  0.05 to 82.24 0.78
Age, years 1.02 0.99 to 1.06 0.19
Sex, female/male 1.03 0.54 to 2.0 0.92
PCRS, PCRS/private 0.63 0.2 to 1.66 0.36
Pulse pressure >60 mmHg, yes/no 0.60 0.31 to 1.12 0.11
ACE inhibitor, yes/no 0.50 0.26 to 0.95 0.04
Calcium channel blockers, yes/no 1.83 0.88 to 3.81 0.11
Diuretic, yes/no 0.39 0.02 to 2.6 0.40
Combination medications, yes/no 0.70 0.34 to 1.39 0.31
aVariables identified previously in the literature 6,11,12that were identified as useful predictors of adherence (Table 3) 
were included in this model. PCRS = primary care reimbursement service. Private = private patient.
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Comparison with existing literature
Jung et al were the first to use mass 
spectrometry urine analysis in patients 
with aTRH,8 when they showed that 53% 
of 78 patients attending a hypertension 
clinic were non-adherent.8 Similarly, 
Tomaszewski et al reviewed 208 patients 
with hypertension attending a hypertension 
clinic and found that 25% were non-
adherent.9 In a methodologically similar but 
larger study (n = 1348), Gupta et al found 
proportions of non-adherence in UK and 
Czech populations attending hypertension 
clinics of 41.6% and 31.5% respectively.6 The 
non-adherence rate found in the present 
study is similar to that of Tomaszewski et al 
and much lower than that of Gupta et al and 
Jung et al.6,8,9 It is intuitive that adherence 
may be higher in primary care than in 
specialist hypertension clinics, where more 
complex patients have been referred for 
assessment. The authors’ recent systematic 
review, based on medication adherence 
rates among patients with aTRH, confirms 
this.19
Certain patients may also improve 
their adherence just before testing — the 
‘tooth-brush effect’.20 Simply, Jung et al 
did not inform patients that adherence 
was being assessed.8 In both Gupta’s and 
Tomaszewski’s studies,6,9 patients were 
explicitly informed that their urine would 
be assessed for drug adherence, albeit just 
before the sample was taken. In this study, 
patients were informed in advance and the 
authors accept that this may potentiate the 
‘tooth-brush effect’. 
Jung et al noted that patients who were 
adherent had significantly lower clinic 
systolic and diastolic BPs.8 Tomaszewski 
et al found significant associations between 
higher adherence and lower clinic and 
24-hour-day BP readings.9 Gupta et al 
found significant associations between 
non-adherence and decreasing age, being 
female, increasing numbers of medications, 
and being prescribed diuretics.6 The 
researchers found no such significant 
associations in the present study. The 
sample size in this study of 235 persons is 
similar to those of Jung and Tomaszewski, 
but smaller than that of Gupta. However, 
the baseline BPs in this primary care 
population were, as expected, much lower 
than those of the specialist settings, 
possibly impacting on the identification of 
any such associations owing to the reduced 
BP variability.
In work based on the Spanish Ambulatory 
Blood Pressure Monitoring Registry, 
de la Sierra, showed that just over one-
third of patients with aTRH (37.5%) had 
WCH.21 This estimate is consistent with the 
findings presented here, and highlights its 
importance.7
Implications for research and practice 
The authors previously examined non-
adherence to therapy in aTRH via meta-
analysis, and found a pooled prevalence 
of non-adherence of 30%.19 Interestingly, 
the strongest contributor to variance in 
non-adherence rates was the method 
of adherence assessment used. Direct 
measures such as urine drug analysis 
gave the highest prevalence. Perhaps 
patients with adherence issues may be 
best identified by a combination of direct 
and indirect methods, such as with mass 
spectrometry urine analysis and the use 
of a valid questionnaire, for example, 
ProMAS Medication Adherence Scale and 
others.22 Interestingly, this type of joint 
assessment gave figures closest to the 
pooled prevalence estimate identified in 
the meta-analysis.19 The authors also 
recently published a comparator article 
between three measures of adherence 
(patient questionnaire, mass spectrometry 
urine analysis, and prescription refill data), 
and found that associations among these 
measures were weak overall.11
Further work is also needed to explore 
how patients and physicians would feel 
about the acceptability of using mass 
spectrometry urine analysis in routine 
consultations. There exists clear potential 
for undermining the patient–doctor 
relationship.7 This is particularly important 
given the limitations of specific drug assays 
outlined above. Mass spectrometry urine 
analysis is currently costly (40–80 GBP per 
sample)8 and explicit cost-effectiveness 
analyses are now required for the primary 
care setting.
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